In RRMM, treatment efficacy diminishes with each successive line of therapy
Your treatment choice at first relapse is a pivotal decision with lasting impact for your patients1
Typical Disease Trajectory of Multiple Myeloma: depth and duration of response2,3
Progressive decline in overall response rates (≥PR):
An International Myeloma Foundation study of 383 patients with multiple myeloma who had a documented relapse between January 2007 and June 2010, including 220 from Europe, 106 from Asia, 31 from South America, and 26 from North America, found a decline in response rates over time from 58% at first relapse to 45% at second relapse and 30% at third relapse.4
RRMM = relapsed/refractory multiple myeloma; M-protein = myeloma protein; g/dL = gram per deciliter; 2L = second line; 3L = third line; 4L = fourth line; PR = partial response.
References: 1. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252-264. 2. Kurtin SE. Relapsed or relapsed/refractory multiple myeloma. J Adv Pract Oncol. 2013;4(suppl 1):5-14. 3. Durie BGM. Concise review of the disease and treatment options: multiple myeloma cancer of the bone marrow. 2018 ed. International Myeloma Foundation website. Accessed September 20, 2022. https://www.myeloma.org/sites/default/files/resource/ConciseReview.pdf. 4. Durie BG, Moreau P, Sonneveld P, et al. Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. J Clin Oncol. 2012;30(15_suppl):8095.